Loading
A phase 1/2 trial of Pembrolizumab, Ipilimumab and Nivolumab in advanced solid tumours, run by ModernaTX, Inc., now recruiting.
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05533697 by ModernaTX, Inc., with 361 participants planned, started 2022-09-01 and due to reach its primary completion in 2032-02-18. Interventions recorded: mRNA-4359, Pembrolizumab, Ipilimumab and Nivolumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Ipilimumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Ipilimumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/